McNeil Manufacturing Changes Will Bring “Major Upgrade” To OTC Brands
This article was originally published in The Tan Sheet
Executive Summary
A "major upgrade on virtually all" McNeil Consumer & Specialty Pharmaceuticals' OTC brands, including Tylenol, Imodium, Pepcid and Motrin, is expected in the "next one to three years," the company announced
You may also be interested in...
Mevacor, Ditropan Switch Discussions With FDA Proceeding Well – J&J
Discussions between FDA and J&J/Merck over the potential Rx-to-OTC switch of cholesterol-reducing statin Mevacor have been moving in a positive direction, J&J Consumer Pharmaceuticals & Nutritional Products Worldwide Chairman Brian Perkins reported
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands